由肠道病毒A71（EV-A71）感染引起的手足口病（HFMD）目前缺乏具体的预防和治疗干预措施。在这里，我们证明片仔癀 (PZH) 可以在细胞水平上剂量依赖性地抑制 EV-A71 复制，导致 Vero 和人横纹肌肉瘤细胞中 EV-A71 病毒蛋白 1 (VP1) 表达和病毒产量显着降低。更重要的是，我们首次证实 PZH 可以保护小鼠免受 EV-A71 感染，并以利巴韦林作为阳性对照。 PZH 治疗降低了 EV-A71 VP1 蛋白表达、受感染肌肉中的病毒产量，并改善了肌肉病理学。此外，我们利用定量蛋白质组学进行了初步机制研究。结果表明，PI3K/AKT/mTOR 和 NF-κB 信号通路的抑制可能有助于 PZH 的抗 EV-A71 活性。这些发现为支持 PZH 在 EV-A71 感染管理中的潜在治疗应用提供了强有力的证据。版权所有 © 2023 Wang、Chen、Wang、Li、Liu、Li、Deng、Dong、Pang、Song、Zhang、Yu 和 Wang。

Hand, foot, and mouth disease (HFMD) caused by enterovirus A71 (EV-A71) infection, currently lacks specific preventive and therapeutic interventions. Here, we demonstrated that Pien Tze Huang (PZH) could dose-dependently inhibit EV-A71 replication at the cellular level, resulting in significant reductions in EV-A71 virus protein 1 (VP1) expression and viral yields in Vero and human rhabdomyosarcoma cells. More importantly, we confirmed that PZH could protect mice from EV-A71 infection for the first time, with Ribavirin serving as a positive control. PZH treatment reduced EV-A71 VP1 protein expression, viral yields in infected muscles, and improved muscle pathology. Additionally, we conducted a preliminary mechanism study using quantitative proteomics. The results suggested that the suppression of the PI3K/AKT/mTOR and NF-κB signaling pathways may contribute to the anti-EV-A71 activity of PZH. These findings provide strong evidence supporting the potential therapeutic application of PZH for EV-A71 infection management.Copyright © 2023 Wang, Chen, Wang, Li, Liu, Li, Deng, Dong, Pang, Song, Zhang, Yu and Wang.